Fosun Pharma (02196.HK): Net profit attributable to parent company of RMB 3.371 billion in 2025, up 21.7% year-over-year

Gelonghui, March 25 — Fosun Pharma (02196.HK) announced that for the fiscal year ending December 31, 2025, it achieved revenue of 41.498 billion RMB, a year-on-year increase of 1.4%; gross profit of 20.698 billion RMB, up 5.9% year-on-year; net profit attributable to shareholders of the parent company was 3.371 billion RMB, a 21.7% increase year-on-year; basic earnings per share were 1.27 RMB, with a proposed final dividend of 0.39 RMB per share (pre-tax).

During the reporting period, the group continued to optimize its innovation and R&D system, focusing on its core pipelines, and improved efficiency through integration of R&D systems. It also accelerated the transformation of innovative technologies and products through diversified and multi-layered innovation models such as independent R&D, collaborative development, licensing, fund incubation, and industrial investment. In 2025, the group’s total R&D investment reached 5.913 billion RMB, a 6.46% increase year-on-year. R&D investment in the pharmaceutical business was 5.361 billion RMB, up 9.19%. Among these, R&D related to innovative drugs totaled 4.303 billion RMB, a 15.98% increase year-on-year, accounting for 72.77% of total R&D investment, an increase of 5.97 percentage points year-on-year, and representing 80.26% of the pharmaceutical R&D expenditure, up 4.70 percentage points.